Stock Evaluator: AnaptysBio, Inc. (ANAB)

AnaptysBio, Inc. ANAB

$46.63 -0.77 -1.62%
November 20, 2026 4:00:01 PM EST November 10, 2021 Volume: 432,444
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Biotechnology

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
AnaptysBio, Inc. discovers and out-licenses therapeutic bodies in the United States. The company manages financial collaborations for Jemperli, a PD-1 antagonist for various solid tumor indications; and Quimilza, an IL-36R antagonist mAb, which has completed two registration-enabling global Phase 3 trials, and GEMINI-1 and GEMINI-2, evaluating the safety and efficacy of Quimilza in patients with generalized pustular psoriasis. It has a collaboration and exclusive license agreement with GSK plc to develop Jemperli as a monotherapy; and an exclusive license agreement with Vanda Pharmaceuticals Inc. for the development and commercialization of Quimilza. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

Commentary & Analysis


Financial Summary

Share Statistics ANAB Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $1,386.3 $203.5 51%
Shares Out (Mil) 35.1 55.2 40%
Institutional Ownership 97.1% 93.3% 72%
Float (Mil) 20.3 40.4 29%
Beta 0.37 1.05 20%
Avg Daily Volume (000s) 415 569 54%
Price Change
(52-week)
26.0% 38.8% 77%
Growth ANAB Industry
Median
Percentile
(All Stocks)
Sales (5yr) 10.9% 13.6% 62%
Net Income (5yr) 45.6% (10.7%) 93%
EPS (5yr) 39.7% 15.4% 88
Dividends (5yr) 0.0% 0.0% 0%
Cash Flow (5yr) (17.5%) (15.7%) 40%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates na 1 1
Current EPS na $3.495 $3.490
Month Ago EPS na $4.350 na
# Rev Up na 0 na
# Rev Down na 1 na
Three Months Ago EPS na ($0.231) na
Year/Year Chg na (62.9%) (42.8%)
Financials ANAB Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) $60 $40 21%
Net Income (TTM) (Mil) $251 ($44) 70%
EPS (TTM) $8.505 ($1.400) 92%
Operating Cash Flow (TTM) (Mil) ($87) ($35) 7%
Net Cash Flow (TTM) (Mil) na $-0 na
Long-Term Debt (Q1) (Mil) $260 $4 52%
Enterprise Value (Q1) (Mil) $1,484 $142 46%
Valuation ANAB Industry
Median
Percentile
(All Stocks)
P/B 66.61 1.96 99%
P/E 6.0 16.9 7%
Dividend Yield 0.0% 0.0% 0%
PEG (5yr hist) 0.1 0.9 6%
Ratios ANAB Industry
Median
Percentile
(All Stocks)
Gross Margin 107.6% 67.6% 100%
Net Margin 417.6% (50.8%) 100%
ROA 76.0% (47.0%) 100%
ROE na (51.8%) na
Liabilities to Assets 93.2% 29.6% 91%
F-Score 1 3 na

AnaptysBio, Inc. did not pass any screens on 11/20/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors